{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 11 of 129', '10.2.3 Medical history', '64', '10.2.4 Height and weight', '64', '10.2.5 Body surface area involvement', '64', '10.3 Efficacy assessments', '65', '10.3.1 Investigator assessments', '65', \"10.3.1.1 Investigator's Global Assessment\", '65', '10.3.1.2 Eczema Area and Severity Index', '65', '10.3.1.3', 'Scoring Atopic Dermatitis', '67', '10.3.1.4', 'Atopic dermatitis flares', '68', '10.3.2', 'Subject assessments', '68', '10.3.2.1 Eczema-related Sleep numeric rating scale', '69', '10.3.2.2 Worst Daily Pruritus numeric rating scale', '69', '10.3.2.3 Average Daily Pruritus numeric rating scale', '69', '10.3.2.4', 'Patient Days of Topical Treatment Use', '69', '10.3.2.5 Patient Global Impression of Bother', '69', '10.3.2.6 Patient Global Impression of Severity', '70', '10.3.2.7', 'Patient-Oriented Eczema Measure', '70', '10.3.2.8', 'Dermatology Life Quality Index', '70', '10.3.2.9', 'EQ-5D-5L', '70', '10.3.2.10 Hospital Anxiety and Depression Scale', '71', '10.4 Safety assessments', '71', '10.4.1 Vital signs', '71', '10.4.2 Physical examination', '72', '10.4.3', 'Digital ECG', '72', '10.4.4', 'Pregnancy test', '73', '10.4.5', 'Laboratory testing', '73', '10.4.6 Pharmacokinetic assessments', '75', '10.4.7 Anti-drug antibodies measurements', '75', '10.5 Estimate of total blood volume collected', '76', '11 Adverse events', '76', '11.1 Collection of adverse events', '76', '11.2 Reporting of adverse events', '77', '11.3 Reporting of serious adverse events', '77', '11.3.1 Investigator reporting responsibilities', '77', '11.3.2 LEO reporting responsibilities', '78', '11.4 Other events that require expedited reporting', '79', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 12 of 129', '11.4.1 Pregnancy', '79', '11.5 Reporting of other events', '79', '11.5.1 Adverse events of special interest', '79', '11.5.2 Overdose', '81', '11.5.3', 'Medication error', '81', '11.5.4', 'Misuse', '81', '11.5.5', 'Abuse', '81', '11.5.6 Aggravation of condition', '82', '11.6 Follow-up for final outcome of adverse events', '82', '11.7 Handling of an urgent safety measure', '82', '12 Statistical methods', '83', '12.1 Sample size', '83', '12.2 Trial analysis sets', '83', '12.3 Statistical analysis', '84', '12.3.1 Disposition of subjects', '84', '12.3.2 Demographics and other baseline characteristics', '85', '12.3.3 Exposure and treatment compliance', '85', '12.3.3.1', 'Exposure', '85', '12.3.3.2', 'Treatment compliance', '85', '12.3.4', 'Multiple testing procedure', '85', '12.3.5', 'Analysis of primary endpoints', '86', '12.3.5.1 Primary estimand: \"composite\\'', '87', '12.3.5.2 Secondary estimand: \"hypothetical\\'', '88', '12.3.5.3 Tertiary estimand: \"treatment policy\\'', '91', '12.3.6 Analysis of secondary endpoints', '92', '12.3.6.1 Primary estimand for the continuous secondary endpoints: \"hypothetical\\'', '92', '12.3.6.2 Secondary estimand for the continuous secondary endpoints: \"treatment policy\\' 94', '12.3.7 Analysis of additional secondary endpoints', '96', '12.3.8 Analysis of other endpoints', '97', '12.3.8.1 Efficacy related other endpoints', '97', '12.3.8.2', 'Patient-reported outcomes', '98', '12.3.9', 'Analysis of safety', '99', '12.3.9.1', 'Adverse events', '99', '12.3.9.2', 'Vital signs', '100', '12.3.9.3', 'Clinical laboratory evaluation', '100', '12.3.9.4 Pharmacokinetics', '100', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}